Jorg J Ruhe1, Thomas Monson, Robert W Bradsher, Anupama Menon. 1. Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA. ruhejorgj@uams.edu
Abstract
BACKGROUND: Few data exist on the efficacy of the long-acting tetracyclines doxycycline and minocycline against methicillin-resistant Staphylococcus aureus (MRSA) infection. METHODS: The medical records of 24 patients with serious tetracycline-susceptible MRSA infections who were treated with doxycycline or minocycline were reviewed. A review of the literature on the use of these antibiotics for treatment of both methicillin-susceptible and methicillin-resistant S. aureus infection was also performed. RESULTS: Complicated skin and skin-structure infections were most common (67%). Clinical cure was achieved in 20 (83%) of 24 patients in our case series. Both drugs were well-tolerated. The review of the literature on a total of 85 patients with S. aureus infection revealed similar results. CONCLUSIONS: Long-acting tetracyclines may be a reasonable treatment alternative for patients with certain types of MRSA infection.
BACKGROUND: Few data exist on the efficacy of the long-acting tetracyclinesdoxycycline and minocycline against methicillin-resistant Staphylococcus aureus (MRSA) infection. METHODS: The medical records of 24 patients with serious tetracycline-susceptible MRSA infections who were treated with doxycycline or minocycline were reviewed. A review of the literature on the use of these antibiotics for treatment of both methicillin-susceptible and methicillin-resistant S. aureus infection was also performed. RESULTS: Complicated skin and skin-structure infections were most common (67%). Clinical cure was achieved in 20 (83%) of 24 patients in our case series. Both drugs were well-tolerated. The review of the literature on a total of 85 patients with S. aureus infection revealed similar results. CONCLUSIONS: Long-acting tetracyclines may be a reasonable treatment alternative for patients with certain types of MRSA infection.
Authors: Mary Jo Cenizal; Daniel Skiest; Samuel Luber; Roger Bedimo; Pat Davis; Patrick Fox; Kathleen Delaney; R Doug Hardy Journal: Antimicrob Agents Chemother Date: 2007-05-14 Impact factor: 5.191
Authors: Michelle Barton; Michael Hawkes; Dorothy Moore; John Conly; Lindsay Nicolle; Upton Allen; Nora Boyd; Joanne Embree; Liz Van Horne; Nicole Le Saux; Susan Richardson; Aideen Moore; Dat Tran; Valerie Waters; Mary Vearncombe; Kevin Katz; J Scott Weese; John Embil; Marianna Ofner-Agostini; E Lee Ford-Jones Journal: Can J Infect Dis Med Microbiol Date: 2006-09 Impact factor: 2.471
Authors: Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe Journal: Am J Pathol Date: 2007-08-23 Impact factor: 4.307